AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06160791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Administered Orally (PO)
Study NCT06160791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered IV
Study NCT06160791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered PO or IV
Study NCT06160791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-interventional Imaging
Description: Participants undergo abdominal ultrasound and/or magnetic resonance imaging (MRI)
Study NCT06160791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research Biopsy
Description: Bone marrow biopsy and lymph node biopsy will be obtained during screening and as clinically indicated throughout the trial.
Study NCT06160791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04828239 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Needle type: C\&G, gauge and size: 0.25x40mm
Study NCT05933720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypeptides
Description: The patients will undergo treatment with a drug based on vascular polypeptides Slavinorm®, a derivative from cattle vessels, registered in Russia for the treatment of patients with peripheral atherosclerotic occlusive disease.
Study NCT04828239 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture
Description: This laser pen is the same device with a red light was pasted on the acu-points in the same way, using the same protocol as for the active laser stimulation, but the laser apparatus was not switched on.
Study NCT04534972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)
Description: Post-implementation of targeted normoxemia through oxygen titration for individual patients. Intervention for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 >96% or PaO2 > 100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air \[no supplemental oxygen\] for non-mechanically ventilated patients).
Study NCT06181591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 MG
Description: Mirabegron (IP: Hibero) is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). It is used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. Through a 8 weeks clinical trial, it aims to evaluate the efficacy and safety of Hibero (Mirabegron), especially in maximum voided volume.
Study NCT05933720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femoral-popliteal bypass grafting with a synthetic graft above the knee
Description: The patients with undergo an arterial revascularization - Femoral-popliteal bypass grafting with a synthetic graft above the knee
Study NCT05933720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral-popliteal bypass grafting with a synthetic graft above the knee
Description: The patients with undergo an arterial revascularization - Femoral-popliteal bypass grafting with a synthetic graft above the knee
Study NCT05933720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine conservative treatment
Description: The patients will undergo routine conservative treatment as per clinical guidelines (acetylsalicylic acid 100mg daily, atorvastatin 20mg daily)
Study NCT04878380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: A consumer sleep tracker will be used to monitor sleep patterns throughout the study
Study NCT04878380 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: A consumer sleep tracker will be used to monitor sleep patterns throughout the study
Study NCT04878380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep education tips
Description: Sleep tips will be provided before the intervention phase
Study NCT04878380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep education tips
Description: Sleep tips will be provided before the intervention phase
Study NCT04878380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-setting
Description: During the intervention phase, the Goal-Setting group will be additionally rewarded for achieving sleep goals, i.e. 30 mins longer than their habitual sleep duration and sleeping before midnight.
Study NCT05583240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essences and Essential Oils
Description: Participants will received Essential Oils through a nasal stick during 4 weeks.
Study NCT06398223 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid endarterectomy (CEA)
Description: Carotid endarterectomy (CEA): Surgical procedure to remove the plaque buildup in the carotid artery.
Study NCT06398223 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid artery stenting
Description: Carotid artery stenting: Treatment of the stenosis with a stent. The plaque in the artery wall is not removed but the narrowing is dilated.
Study NCT06181591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin Chloride 5 MG
Description: Oxybutynin has been used to treat overactive bladder (OAB). The subject will take 5 mg of Ditropan (Oxybutynin Chloride) twice a day, in total of 10 mg for 8 weeks.
Study NCT04866056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Jaktinib PO BID
Study NCT04866056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Azacytidine SC
Study NCT05722093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manzi Guben granules
Description: Administration cycle of Manzhi Guben granules: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
Study NCT05722093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Manzi Guben granules
Description: Administration cycle of Manzhi Guben granules: 1-4 weeks; Usage: 10g once, twice a day, washed with boiling water.
Study NCT06000397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced reminders
Description: The intervention is sending enhanced (modality and frequency) of reminders to CANImmunize App users, in addition to the standard notifications. Specifically:~* Deliver reminders and recall emails to parents or guardians of infants waiting for their 12-month dose of pneumococcal vaccine,~* Add additional information about the benefits, safety and effectiveness of the pneumococcal vaccine to support increased uptake, and~* Provide tips to improve parents' or guardians' self-efficacy in circumventing barriers to timely immunization of children at the 12-month's visit
Study NCT06000397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard CANImmunize notifications
Description: Push notifications at two time points:~* two weeks prior to the immunization due date~* one week after the immunization due date
Study NCT04768075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
Study NCT04768075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion Simulator of Camrelizumab
Study NCT04768075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT04768075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT04768075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT04768075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT04768075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT04768075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion
Study NCT04768075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT04768075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study NCT04768075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: IV infusion
Study NCT04768075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin paclitaxel
Description: IV infusion
Study NCT06333301 — intervention group
Intervention type: OTHER
Intervention: Surveys
Description: Group will complete several surveys
Study NCT06095310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New computer vision methods
Description: Clinical interview: Hamilton scale using multi-modal sensors (cameras, audio, bracelet, fNIRS)
Study NCT05302843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-28592
Description: Characterize the pharmacokinetics (PK)，safety，antitumor activity of BPI-28592
Study NCT05641948 — intervention group
Intervention type: OTHER
Intervention: MRI scan
Description: Participants will undergo brain MRI scan at 3 intervals
Study NCT05224089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivicaine/Bupivacaine Admixture
Description: 60mL of 0.25% Bupivacaine (150mg)+ 20 mL of 1.3% Exparel (266 mg)+20mL NS=100mL
Study NCT05224089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCL
Description: 80mL 0.25% bupivacaine (200mg) + 300mcg (0.3mL) epinephrine + 5mg (0.5mL) preservative free dexamethasone + 20mL NS= 100mL
Study NCT04545866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide (Pulmicort nebulizing suspension).
Description: The first dose of budesonide is 0.25 mg/kg in a volume of 1 ml/kg, for a total volume of 2.5 ml/kg of Curosurf + 1 ml/kg of budesonide. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose and 1 ml/kg of budesonide.
Study NCT04545866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: surfactant (poractant alfa;Curosurf)
Description: The first dose of surfactant (poractant alfa; Curosurf) is 2.5 ml/kg. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose.
Study NCT06029114 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Elastography (MRE)
Description: Imaging technique performed on a Compact 3T MRI scanner that measures the stiffness (mechanical properties) of tissues.
Study NCT04978467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton
Description: Participants will receive assistance to move finger joints away from the compensatory coordination (compensation avoidance), toward the desired trajectories (task assistance), both, and none in different days.
Study NCT06131840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-08046050
Description: Given into the vein (IV; intravenous)
Study NCT06079255 — intervention group
Intervention type: DEVICE
Intervention: IscAlert sensor(s) in patient with risk of acute compartment syndrome
Description: of the replanted extremity Insertion of a CO2- and temperature sensor(s) (IscAlert) in the anterior compartment of a lower limb (leg)
Study NCT05224089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCL
Description: 80mL 0.25% bupivacaine (200mg) + 300mcg (0.3mL) epinephrine + 5mg (0.5mL) preservative free dexamethasone + 20mL NS= 100mL
Study NCT05559398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glenzocimab
Description: Glenzocimab (ACT-017, Acticor Biotech) is formulated for IV administration as a sterile product with 20 mM sodium citrate and 130 mM sodium chloride buffer at pH of 5.0.~It is supplied for clinical trial use in vials containing 50 mL of the drug product at a concentration of 10 mg/mL.~Each vial contains 500 mg of glenzocimab. Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total daily dose of 1g.~Glenzocimab is intended to be administered as an IV infusion over 6 hrs, with 1/4 of the dose administered by a 15-minute bolus and 3/4 of the dose administered by 5h45min-slow infusion.
Study NCT05838456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viz.AI software
Description: Viz.AI software performs artificial intelligence-based automated detection of large vessel occlusions and alerts the AIS care team.
Study NCT05589259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Brachial Plexus Block plus Physiotherapy
Description: Participants will receive a single-shot axillary-approach brachial plexus block. For the procedure, a 22g or larger peripheral intravenous cannula will be placed, and skin will be sterilized with chlorhexidine. Using aseptic technique, the anesthesiologist will anesthetize the skin and tract with 5cc of 1% lidocaine using a 25g 1.5 needle. After this, a 50mm 21g Pajunk needle will be guided under ultrasound with an in-plane technique to anesthetize the median, ulnar, radial, and musculocutaneous nerves. Identification of the axillary artery, vein and surrounding vessels will be done to ensure an intravascular injection is avoided. Once proper location is confirmed, the anesthesiologist will aspirate to ensure the needle is not intravascular. Once aspiration is confirmed negative, bupivacaine 0.25% 1.5mg/kg (lean body weight) will be injected in divided doses.~30 minutes after placement of the block, the standardized physiotherapy protocol will begin.
Study NCT05589259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy alone
Description: Participants in the EXP arm and the CON arm will complete the same physiotherapy program.~PHYSIOTHERAPY PROTOCOL The physiotherapy program will include manipulation with or without a block. The goal of manipulation is to break up adhesions, possibly overcoming microvascular dysfunction. After the manipulation, participants will take part in a 6-week program which will include a weekly one-hour session with a physiotherapist at the KHSC-CPC and a home exercise program (HEP). During each session, the physiotherapist will work with the participants to increase ROM and limb function using manual therapy, stretching, and strengthening exercises specific to the affected joint(s) and most importantly using GMI. At the end of each session, the physiotherapist will prescribe exercises to complete at home.
Study NCT04876937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is infused at a rate of 0.1-0.2 μg/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
Study NCT05559398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of glenzocimab is 0.9%NaCl (Acticor Biotech) for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo of glenzocimab should be administered concomitantly for eligible patients.
Study NCT04979104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip arthroplasty with SL Cementless
Description: Total or partial hip arthroplasty with implant of SL cementless femoral stem.
Study NCT05273333 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultra-gyn®
Description: Ultra-gyn® ovule intravaginal application, every evening before bedtime for a 10 days period.
Study NCT06487416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Inhalation Powder
Description: By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
Study NCT06487416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva®Handihaler®
Description: By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
Study NCT06468852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy
Description: Stroke volume variation (SVV)≤12% and cardiac index (CI)≥2.5L/min/m2 are the goals of Goal-Directed fluid therapy, while the mean arterial pressure (MAP) are kept between 65 and 90 mmHg. 5mL/kg of crystalloids will be infused during induction period, followed by an infusion rate of 2 mL/kg/h to supplement the physiological requirements. If SVV>12% for more than 5 min, a 250 mL bolus of colloid is given. Another 250 ml bolus of colloid is administrated if SVV was still more than 12% or SV decreased over 10%. If the CI\<2.5 L/min/m2, inotropes are used to achieve this minimum CI, serving as a safety parameter to prevent the patient from being exposure to a low cardiac output state. If SVV and CI reached the s target range but MAP could not maintain the expected level, vasopressors were started. Assess the patients every 5min intraoperatively to ensure that all parameters adhere to the target range according to the study algorithm.
Study NCT05280171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teach back
Description: Discharge information was explained by the principal investigator. On the day of discharge, pictographs teach back regarding medication, exercise, diet and follow-up was given and they were asked teach back.~Teach back is a approach which is used in cognitive psychology experiments describing repeating short sequences of information helps to improve repeat back of information. This teach back technique is recommended as a universal precaution by the agency for healthcare research and quality and the national quality forum.
Study NCT05280171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT05818098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular Lithotripsy System of Shanghai MicroPort Rhythm
Description: The Intravascular Lithotripsy System is a single-use, sterile, disposable balloon angioplasty catheter that contains a series of unfocused, electrohydraulic lithotripsy emitters, which convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within vascular plaque.
Study NCT06444009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab combined with TP
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
Study NCT06444009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab combined with TP
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
Study NCT05170893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Oral capsules
Study NCT05170893 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study NCT06444009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab combined with TP
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
Study NCT06200402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic loaded
Description: This is the intervention for the study group. It involves the use of bone cement mixed with antibiotics (typically gentamicin or similar) in the hip prosthesis surgery. The purpose of this intervention is to assess whether the antibiotic-loaded cement reduces the incidence of postoperative infections compared to standard cement
Study NCT06200402 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04876937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Placebo (normal saline) is infused at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 7 days.
Study NCT04079582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L).
Description: (Dialysate magnesium concentration currently used in Canada and the United States)
Study NCT04079582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L).
Description: (Dialysate magnesium concentration currently used in Canada and the United States)
Study NCT05868993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose of 0.5% Ropivacaine
Description: Dose varied by 5mL of 0.5% Ropivacaine
Study NCT03926819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HBI-002
Description: Oral liquid carbon monoxide drug product.
Study NCT06554639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5684
Description: Administered via oral tablet per dosing regimen.
Study NCT05566847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician Education
Description: The physician education session delivered to primary care physicians in Arms 2 and 3 will provide an educational update from the regional clinical leader for diabetes regarding guidelines for diabetes treatment and addressing therapeutic inertia.
Study NCT05767216 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological sampling
Description: Blood, skin and stool samples for laboratory analysis
Study NCT04999696 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical hysterectomy
Description: To compare disease-free survival and overall survival of patients with early stage cervical cancer undergoing total laparoscopic radical hysterectomy versus total abdominal radical hysterectomy